Trial Watch: experimental TLR7/TLR8 agonists for oncological indications.
CGAS
Cancer immunotherapy
danger signaling
immune checkpoint blockers
immunogenic cell death
type I interferon
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
21 07 2020
21 07 2020
Historique:
entrez:
16
9
2020
pubmed:
17
9
2020
medline:
17
9
2020
Statut:
epublish
Résumé
Resiquimod (R848) and motolimod (VTX-2337) are second-generation experimental derivatives of imiquimod, an imidazoquinoline with immunostimulatory properties originally approved by the US Food and Drug Administration for the topical treatment of actinic keratosis and genital warts more than 20 years ago. Both resiquimod and motolimod operate as agonists of Toll-like receptor 7 (TLR7) and/or TLR8, in thus far delivering adjuvant-like signals to antigen-presenting cells (APCs). In line with such an activity, these compounds are currently investigated as immunostimulatory agents for the treatment of various malignancies, especially in combination with peptide-based, dendritic cell-based, cancer cell lysate-based, or DNA-based vaccines. Here, we summarize preclinical and clinical evidence recently collected to support the development of resiquimod and motolimod and other TLR7/TLR8 agonists as anticancer agents.
Identifiants
pubmed: 32934889
doi: 10.1080/2162402X.2020.1796002
pii: 1796002
pmc: PMC7466852
doi:
Substances chimiques
Adjuvants, Immunologic
0
Antineoplastic Agents
0
Toll-Like Receptor 7
0
Toll-Like Receptor 8
0
Imiquimod
P1QW714R7M
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Review
Langues
eng
Pagination
1796002Informations de copyright
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
Références
MAbs. 2020 Jan-Dec;12(1):1725346
pubmed: 32054397
Clin Cancer Res. 2007 Dec 1;13(23):7119-25
pubmed: 18056192
Immunity. 2016 Apr 19;44(4):739-54
pubmed: 27096317
Immunotherapy. 2014;6(10):1085-95
pubmed: 25428647
Blood. 1990 Aug 1;76(3):473-9
pubmed: 2378980
Nat Rev Immunol. 2020 Jan;20(1):7-24
pubmed: 31467405
Nat Rev Immunol. 2006 Mar;6(3):196-204
pubmed: 16498450
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32209603
J Clin Neurosci. 2018 Oct;56:139-142
pubmed: 29960842
JAMA Oncol. 2018 Nov 1;4(11):1569-1575
pubmed: 30098152
J Immunol. 2000 Jul 15;165(2):618-22
pubmed: 10878331
Oncoimmunology. 2019 Apr 19;8(7):1601480
pubmed: 31143525
Oncoimmunology. 2018 Aug 15;7(10):e1472187
pubmed: 30288341
Nat Rev Drug Discov. 2020 Mar;19(3):185-199
pubmed: 31900462
Oncoimmunology. 2018 Oct 29;8(2):e1532763
pubmed: 30713786
Int Rev Cell Mol Biol. 2019;348:217-262
pubmed: 31810554
Nat Rev Cardiol. 2020 Aug;17(8):474-502
pubmed: 32231332
Oncol Res Treat. 2018;41(5):306-312
pubmed: 29742518
Trends Cell Biol. 2019 May;29(5):396-416
pubmed: 30765144
Int Rev Cell Mol Biol. 2019;345:225-285
pubmed: 30904194
Nat Rev Clin Oncol. 2011 May 24;8(9):551-61
pubmed: 21606971
Nat Rev Drug Discov. 2012 Jun 29;11(7):503-5
pubmed: 22743965
Nat Rev Immunol. 2020 Jan;20(1):25-39
pubmed: 31570880
Nat Rev Immunol. 2020 Feb;20(2):95-112
pubmed: 31558839
J Control Release. 2019 Jul 28;306:165-176
pubmed: 31173789
Nat Commun. 2020 Jan 31;11(1):661
pubmed: 32005826
Nat Rev Gastroenterol Hepatol. 2020 May;17(5):263-278
pubmed: 32103203
Nat Rev Cancer. 2007 Feb;7(2):95-106
pubmed: 17251916
Cancer Res. 2017 Jun 1;77(11):2869-2880
pubmed: 28364003
Nat Rev Immunol. 2016 Sep;16(9):566-80
pubmed: 27455396
EMBO J. 2018 Jul 13;37(14):
pubmed: 29875130
Nat Rev Immunol. 2019 Mar;19(3):141-153
pubmed: 30644449
J Clin Pharmacol. 2008 Jun;48(6):755-62
pubmed: 18401016
Science. 2010 Jan 15;327(5963):291-5
pubmed: 20075244
Br J Cancer. 2018 Mar 6;118(5):654-661
pubmed: 29438373
Nat Rev Immunol. 2020 Feb;20(2):75-76
pubmed: 31925406
Nat Rev Immunol. 2007 May;7(5):353-64
pubmed: 17457343
Annu Rev Microbiol. 2018 Sep 08;72:447-478
pubmed: 30200854
Nat Rev Drug Discov. 2018 Oct;17(10):751-767
pubmed: 30190565
Nat Rev Drug Discov. 2006 Jun;5(6):471-84
pubmed: 16763660
Front Immunol. 2014 Sep 25;5:461
pubmed: 25309543
Int Rev Cell Mol Biol. 2019;348:179-215
pubmed: 31810553
Cancer Res. 2007 Jul 1;67(13):6253-62
pubmed: 17616683
Nat Rev Clin Oncol. 2020 Jan;17(1):33-48
pubmed: 31548601
Acta Pharmacol Sin. 2020 Jul;41(7):995-1004
pubmed: 32451412
Oncoimmunology. 2018 Feb 14;7(6):e1431088
pubmed: 29872559
Int Rev Cell Mol Biol. 2019;342:149-173
pubmed: 30635090
PLoS One. 2016 Jun 30;11(6):e0158617
pubmed: 27359113
Nat Rev Clin Oncol. 2019 Mar;16(3):151-167
pubmed: 30523282
Oncoimmunology. 2020 Feb 20;9(1):1731072
pubmed: 32158623
Eur J Med Chem. 2020 May 1;193:112238
pubmed: 32203790
Sci Transl Med. 2020 Jan 22;12(527):
pubmed: 31969486
Annu Rev Immunol. 2018 Apr 26;36:667-694
pubmed: 29677479
Nat Rev Immunol. 2017 Feb;17(2):97-111
pubmed: 27748397
Nat Rev Immunol. 2013 Jun;13(6):453-60
pubmed: 23681101
Int Rev Cell Mol Biol. 2019;344:139-172
pubmed: 30798987
Oncoimmunology. 2018 Mar 06;7(6):e1438107
pubmed: 29930882
MAbs. 2020 Jan-Dec;12(1):1703531
pubmed: 31847708
Nat Rev Urol. 2020 Mar;17(3):137-150
pubmed: 32020040
Nat Rev Clin Oncol. 2020 Aug;17(8):504-515
pubmed: 32246128
Science. 2002 Apr 12;296(5566):301-5
pubmed: 11951032
Am J Hematol. 2012 Oct;87(10):953-6
pubmed: 22718533
Nat Rev Immunol. 2015 Jul;15(7):405-14
pubmed: 26027717
PLoS One. 2016 Feb 29;11(2):e0148764
pubmed: 26928328
Oncoimmunology. 2019 Sep 7;8(11):e1657375
pubmed: 31646107
Front Immunol. 2019 Jul 23;10:1705
pubmed: 31396221
Cell. 2015 Apr 9;161(2):205-14
pubmed: 25860605
Nat Rev Clin Oncol. 2015 Oct;12(10):563
pubmed: 26305037
Cancer. 2019 Jan 15;125(2):278-289
pubmed: 30343509
Front Immunol. 2019 Jul 03;10:1505
pubmed: 31333652
Clin Cancer Res. 2017 May 15;23(10):2442-2450
pubmed: 27810904
Eur J Immunol. 2019 Nov;49(11):2083-2094
pubmed: 31393597
Nat Rev Immunol. 2020 Nov;20(11):669-679
pubmed: 32346095
Nat Rev Drug Discov. 2019 Nov;18(11):845-867
pubmed: 31554927
Immunity. 2008 Mar;28(3):315-23
pubmed: 18342006
Cell. 2016 Mar 10;164(6):1233-1247
pubmed: 26967289
Radiother Oncol. 2019 Nov;140:116-124
pubmed: 31271996
Nat Rev Cancer. 2012 Dec;12(12):860-75
pubmed: 23151605
Annu Rev Immunol. 2016 May 20;34:265-97
pubmed: 26907214
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32179633
Oncoimmunology. 2017 Nov 20;6(12):e1398878
pubmed: 29209575
Annu Rev Immunol. 2018 Apr 26;36:717-753
pubmed: 29490164
J Interferon Cytokine Res. 2008 Apr;28(4):253-63
pubmed: 18439103
Cell Rep. 2019 Oct 29;29(5):1261-1273.e6
pubmed: 31665638
Nat Rev Microbiol. 2010 Jan;8(1):8-14
pubmed: 19946286
J Clin Pharmacol. 2007 Aug;47(8):962-9
pubmed: 17660481
Nat Rev Drug Discov. 2011 Feb;10(2):127-40
pubmed: 21283107
Oncogene. 2019 Mar;38(13):2380-2393
pubmed: 30518877
Oncoimmunology. 2019 Jun 6;8(9):e1624128
pubmed: 31428520
Mol Cell Oncol. 2015 Jun 10;3(1):e1057315
pubmed: 27308571
Nat Med. 2017 May 5;23(5):540-547
pubmed: 28475571
Front Immunol. 2015 Nov 20;6:588
pubmed: 26635802
Int Rev Cell Mol Biol. 2019;348:123-178
pubmed: 31810552
J Clin Oncol. 2005 Jul 20;23(21):4602-8
pubmed: 16034041
BMC Immunol. 2008 Jul 24;9:39
pubmed: 18652679
Vaccine. 2007 Sep 27;25 Suppl 2:B72-88
pubmed: 17916464
Oncoimmunology. 2018 Oct 1;8(1):e1510710
pubmed: 30546946
Nat Rev Drug Discov. 2005 Nov;4(11):879-80
pubmed: 16299917
Nat Rev Immunol. 2015 Feb;15(2):87-103
pubmed: 25614319
Klin Khir. 1989;(8):13-5
pubmed: 2509780
Int Rev Cell Mol Biol. 2019;348:1-68
pubmed: 31810551
Oncoimmunology. 2015 Jun 3;4(7):e1058037
pubmed: 26140249
J Mater Chem B. 2019 Apr 21;7(15):2499-2511
pubmed: 32255127
J Immunol. 2006 Jan 1;176(1):157-64
pubmed: 16365406
Oncoimmunology. 2018 Aug 27;7(12):e1503032
pubmed: 30524901
Clin Cancer Res. 2008 Feb 1;14(3):856-64
pubmed: 18245549
Skin Therapy Lett. 2001 Mar;6(6):1-4
pubmed: 11298484
Oncoimmunology. 2018 Oct 11;7(12):e1526250
pubmed: 30524908
Int Rev Cell Mol Biol. 2019;344:31-89
pubmed: 30798990
Nat Rev Urol. 2013 Sep;10(9):537-45
pubmed: 23979666
Nat Rev Clin Oncol. 2010 Nov;7(11):621-2
pubmed: 20981127
Mucosal Immunol. 2014 Mar;7(2):215-26
pubmed: 24150257
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Clin Pharmacol Ther. 2011 Jun;89(6):821-9
pubmed: 21451504
Front Plant Sci. 2017 Jan 11;7:2061
pubmed: 28123393
JAMA Oncol. 2018 Nov 1;4(11):1583-1588
pubmed: 29931076
J Urol. 2013 May;189(5):1682-6
pubmed: 23123547
Int Rev Cell Mol Biol. 2019;345:1-33
pubmed: 30904191
Nat Rev Immunol. 2019 Feb;19(2):73-74
pubmed: 30631206
Oncoimmunology. 2020 Jan 9;9(1):1703449
pubmed: 32002302
Oncoimmunology. 2016 May 31;5(7):e1189051
pubmed: 27622045
Nat Immunol. 2020 Feb;21(2):120-134
pubmed: 31873291
Nat Rev Drug Discov. 2010 Apr;9(4):293-307
pubmed: 20380038
Oncoimmunology. 2018 Sep 6;7(12):e1511506
pubmed: 30524907
Blood. 2019 Oct 3;134(14):1114-1115
pubmed: 31582369
Oncoimmunology. 2018 Feb 20;7(6):e1434467
pubmed: 29872573
Int Rev Cell Mol Biol. 2019;344:173-214
pubmed: 30798988
J Immunother Cancer. 2019 Sep 3;7(1):235
pubmed: 31481112
Drugs. 2018 Jul;78(10):1057-1062
pubmed: 29943374
Science. 1998 Dec 11;282(5396):2085-8
pubmed: 9851930
Int J Dermatol. 2019 Apr;58(4):400-407
pubmed: 30070357
Oncoimmunology. 2018 Aug 24;7(11):e1494112
pubmed: 30377562
BMC Plant Biol. 2016 Oct 26;16(1):232
pubmed: 27782807
Sci Transl Med. 2018 Sep 19;10(459):
pubmed: 30232229
Nat Rev Dis Primers. 2020 May 7;6(1):38
pubmed: 32382051
Expert Opin Investig Drugs. 2017 Dec;26(12):1317-1319
pubmed: 29046065
Cancer Metastasis Rev. 2011 Mar;30(1):13-25
pubmed: 21271351
Annu Rev Immunol. 2017 Apr 26;35:149-176
pubmed: 28125356
Int Rev Cell Mol Biol. 2019;344:1-30
pubmed: 30798985
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373
Int Rev Cell Mol Biol. 2019;348:69-121
pubmed: 31810556
Sci Transl Med. 2015 Apr 22;7(284):284ra58
pubmed: 25904742
Oncoimmunology. 2013 Oct 1;2(10):e25771
pubmed: 24286020